Agios Pharmaceuticals Stock News

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

Physicians’ Education Resource® Launches “Oncology NOW” Webcast Series

Technically speaking, the U.S. benchmarks’ bigger-picture backdrop continues to strengthen amid market rotation, writes Michael Ashbaugh.

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

– Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months – – Vorasidenib Demonstrated a.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE:...

Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Technically speaking, the S&P 500 has cleared major resistance, rising to a potentially consequential test of its 200-day moving average, writes Michael...

Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector. Surface Oncology Inc (...

Is (AGIO) Outperforming Other Medical Stocks This Year?

– TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma – CAMBRIDGE, Mass., May 19, 2020 -- Agios.